Compass Therapeutics, Inc. (CMPX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.86

From 52W high−71.60%

Volume7.81M

Market cap$342.17M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.86

From 52W high

−71.60%

Volume

7.81M

Market cap

$342.17M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.4x

P/E (TTM)

—

RSI (14)

31.7

MomentumView details →

1D Return

+2.70%

YTD Return

−66.01%

SummaryUpdated Jun 1, 2026

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Boston, Massachusetts. The company went public in April 2021 and focuses on developing innovative antibody-based therapeutics for cancer treatment. As a pre-revenue biotechnology firm, Compass is currently advancing multiple drug candidates through various phases of clinical trials, with a particular emphasis on novel approaches to oncology treatment through bispecific antibodies and immune system modulators.

Ask drillr about Compass Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−44.23%

ROA (TTM)

−38.62%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+6.99%

FCF YoY

−21.49%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

−16.67%

EBITDA YoY

−13.95%

MomentumView details →

1D Return

+2.70%

YTD Return

−66.01%

1Y Return

−46.16%

RSI (14)

31.7

vs 50D SMA

−15.80%

vs 200D SMA

−52.40%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

11.22x

Quick Ratio

11.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

−17.47%

Beats (12Q)

5/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

7.40%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−73.45M

Op. CF (TTM)

−54.79M

Next earningsNov 4, 2026 →

Latest newsMore news →

Compass Therapeutics reported a net loss of $25.2 million for Q2 2026, with diluted EPS of -$0.13, and held $180 million in cash and marketable securities at quarter end.46d ago

Similar companies

Lexeo Therapeutics, Inc. Common StockLXEO Century Therapeutics, Inc.IPSC Evommune, Inc.EVMN Alpha Tau Medical Ltd.DRTSW B&K Corporation Limited02396.HK EyePoint Pharmaceuticals, Inc.EYPT Find similar companies →

Latest newsMore news →

Compass Therapeutics reported a net loss of $25.2 million for Q2 2026, with diluted EPS of -$0.13, and held $180 million in cash and marketable securities at quarter end.46d ago